Area of research
Molecular Biology · Oncology
Research interest
Research interests include Cancer research, Biology, Cancer, Ovarian cancer, Gene knockdown, and Metastasis.
Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments
Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment
PDE7A inhibition suppresses triple-negative breast cancer by attenuating de novo pyrimidine biosynthesis
Roles and therapeutic targeting of ceramide metabolism in cancer
IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability
Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment
HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B
CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer
ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE
UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress
Epigenetic regulation and targeting of ECM for cancer therapy
Transcriptional determinants of cancer immunotherapy response and resistance
EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner
PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1
The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis
KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity
LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1
Transcriptional regulators and alterations that drive melanoma initiation and progression
Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R
Identification of the Mutational Landscape of Gynecological Malignancies
Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A
PTEN functions as a melanoma tumor suppressor by promoting host immune response